Skip to main content
. 2023 Feb 9;11(2):e780. doi: 10.1002/iid3.780

Figure 2.

Figure 2

The pooled rate of Hepatitis B virus (HBV) reactivation among HBsAg‐/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis (RA).